Become A Featured Company

Emerald Health Expands Capabilities with Northern Vine Labs Deal

Ryan Allway

November 1st, 2017

Exclusive, News, Top News

Emerald Health Therapeutics Inc. (TSX-V: EMH) (OTCQX: EMHTF) and Abbatis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) recently announced a deal to grow Northern Vine into a thriving center for analytical testing, genetic research and development, tissue culture, and proprietary medicinal and therapeutic formulations. As a Licensed Dealer, Northern Vine will also be able to export and import cannabis oils around the world, unlike ACMPR licensed producers.

Under the agreement, Emerald Health will invest $2.5 million to acquire 53% of Northern Vine and appoint three of four directors. Abattis will continue to hold the remaining 47% equity stake in Northern Vine and benefits from the deal in a variety of other ways. Meanwhile, Emerald Health plans to utilize Northern Vine for cannabis testing, product innovation, and potentially import/export capabilities for cannabis oils.

In this article, we will look at some of the benefits of the transaction for both parties and why investors may want to take notice.

Broadening Licensing Capabilities

Emerald Health benefits from a Licensed Dealer that has much broader capabilities than a Licensed Producer when it comes to carrying out research and development, importing and exporting cannabis oils, and related activities. Northern Vine also provides exposure to the cannabis testing industry, as it currently provides LPs and registered patients with complete microbiology and chemical analyses to ensure product is safe and efficacious.

“Our acquisition of control of Northern Vine will set the wheels in motion on a number of strategic business opportunities that we have been nurturing,” said Emerald Health Executive Chairman Avtar Dhillon, MD, in a press release announcing the deal. “We see tremendous synergies and opportunities to work with Abattis both on extraction and research and development of medicinal and therapeutic products.”

In addition to the Northern Vine transaction, Emerald Health has been working to dramatically expand its cannabis production capacity with a new facility on its 32-acre property in Metro Vancouver and its partnership with Village Farms, which utilizes an existing 25-acre greenhouse complex that is being retrofitted to grow cannabis. The company is focused on high-quality product innovation particularly for wellness and medical benefit to set it apart from many licensed producers in the space that are focused on scale.

Opening the Door to the Future

Abattis Bioceuticals benefits from Emerald Health’s wealth of scientific knowledge, pharmaceutical connections, and access to capital, as well as a $2.5 million capital infusion into the subsidiary. The strong relationship between Abattis and a rapidly growing and respected licensed producer in Canada also paves the way for future joint ventures for its extraction technology and adds credibility to its ability to create laboratories – which is essential to its business model moving forward.

“This is an important turning point for Abattis,” said Robert Abenante, President and CEO of Abattis and Northern Vine. “The company has always desired a strategic partner for its laboratory and has now partnered with one of the most experienced LPs in Canada. As we commence rolling out our business model for extraction, attracting a partner like Emerald is proof that we have an extremely talented team.”

In addition to Northern Vine, Abattis has licensed a proprietary extraction technology with a patented counter-current layering system that yields 98% of cannabinoids – 18% better than today’s leading methods. A continuous system of columns can either remove impurities and pesticides from full spectrum oil or individual cannabinoids and terpenes to 99% purity levels. And, it’s at a lower cost than traditional CO2 extraction methods.

Abattis believes that a major growth area of the industry moving forward lies in the extraction of active ingredients from cannabis to create products such as edibles and the company’s previously announced CBD-based sunscreen. The new relationship with Emerald Health should provide the company with products to test and biomass to convert to those products, utilizing the patented extraction tech to further the company’s stated goal of becoming a key downstream service and products provider.

Looking Ahead

Abbatis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) and Emerald Health Therapeutics Inc. (TSXV: EMH) (OTCQX: EMHTF) both represent compelling investment opportunities in Canada’s cannabis industry. With Emerald Health’s investment in Northern Vine, both companies are better positioned to execute their long-term vision in an industry that Deloitte expects will exceed $22.6 billion over the coming years following adult-use legalization.

For more information about Emerald Health, visit the company’s website or investor presentation.

For more information about Abattis Bioceuticals, visit the company’s website or investor presentation.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading